Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bioadv.2024.213772 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Retracted] Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib.
Oncol Rep
March 2025
Key Laboratory of Hepatobiliary and Pancreatic Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University (Army Medical University), Shapingba, Chongqing 400038, P.R. China.
Following the publication of the above article, the authors noticed that they had inadvertently included a duplication of the same data in Fig. 3C, portraying colony formation experiments, where the results from differently performed experiments were intended to have been shown, and requested that a corrigendum be published to present the data in this figure accurately. Having investigated this matter in the Editorial Office, however, additional panels of overlapping data were identified, comparing between Figs.
View Article and Find Full Text PDFCorrigendum to " antiplasmodium and antitrypanosomal activities, β-haematin formation inhibition, molecular docking and DFT computational studies of quinoline-urea-benzothiazole hybrids" [Heliyon Volume 10, Issue 19, October 2024, Article e38434].
Heliyon
December 2024
School of Chemistry and Physics, University of KwaZulu Natal, Westville Campus, Durban, 4000, South Africa.
[This corrects the article DOI: 10.1016/j.heliyon.
View Article and Find Full Text PDFCorrigendum to "Surface modification of rare earth Sm-doped WO films through polydopamine for enhanced electrochromic energy storage performance" [J. Colloid Interface Sci. 649 (2023) 510-518].
J Colloid Interface Sci
December 2024
Engineering Research Center for Hydrogen Energy Materials and Devices, College of Rare Earths, Jiangxi University of Science and Technology, 86 Hong Qi Road, Ganzhou 341000, PR China. Electronic address:
Corrigendum to "Suppression of TLR4 prevents diabetic bone loss by regulating FTO-mediated mA modification" [Int. Immunopharmacol. 122 (2023) 110510].
Int Immunopharmacol
January 2025
Department of Endocrinology, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China; Department of Endocrinology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou 350212, China; Clinical Research Center for Metabolic Diseases of Fujian Province, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China; Fujian Key Laboratory of Glycolipid and Bone Mineral Metabolism, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China; Diabetes Research Institute of Fujian Province, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China; Metabolic Diseases Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!